RxDoctor Payments Data

Andrew Williams, MD

Glaucoma Specialist · Pittsburgh, PANPI 1669826681

Payments from drug & device makers

What this record shows

7 manufacturers reported payments, led by Alcon Research LLC at 27.5% of the total.

$3,805in general payments, 2019–2025

Across 23 payments — averaging $165.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon Research LLC$1K
  • NEW World Medical,inc.$777
  • Glaukos Corporation$715
  • Alcon$577
  • Sight Sciences, Inc.$348
  • AbbVie$329
  • plus $12 from 1 others

What the payments were for

  • Consulting fees$1,74646%
  • Food & beverage$2,05854%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Pennsylvaniato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$132,775
Medicare patients
319
Services billed
1,212

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost252$126,721
RocklatanNetarsudil Mesylat/Latanoprost143$63,959
Cyclosporine69$46,847
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol140$35,302
RestasisCyclosporine34$34,318
XiidraLifitegrast25$29,204
RhopressaNetarsudil Mesylate77$28,631
CombiganBrimonidine Tartrate/Timolol57$18,188
VyzultaLatanoprostene Bunod47$17,671
Latanoprost1,072$17,440
Brimonidine Tartrate477$16,129
SimbrinzaBrinzolamide/Brimonidine Tart54$14,629
Travoprost57$13,909
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat627$12,389
Prednisolone Acetate176$8,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$329$179,227343 claims
AlconSimbrinza$577$14,62954 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Pennsylvaniaon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →